|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Briviact
gptkb:Phenytoin
|
|
gptkbp:activities
|
S V2 A ligand
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:United_States
2016-02-29
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Briviact
|
|
gptkbp:class
|
anticonvulsants
|
|
gptkbp:clinical_trial
|
Phase III
seizure control
|
|
gptkbp:combatants
|
high
|
|
gptkbp:composed_of
|
from 2-oxo-1-pyrrolidine acetic acid
|
|
gptkbp:contraindication
|
hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:UCB_Pharma
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:education
|
recognizing side effects
importance of adherence
drug interactions awareness
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:software_framework
tablets
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
brivaracetam
|
|
gptkbp:indication
|
partial-onset seizures
|
|
gptkbp:ingredients
|
C12 H14 N2 O2
|
|
gptkbp:interacts_with
|
CY P2 C19 inhibitors
CY P3 A4 inducers
|
|
gptkbp:is_atype_of
|
N03 A X22
|
|
gptkbp:is_monitored_by
|
side effects
seizure frequency
|
|
gptkbp:is_used_for
|
gptkb:psychologist
|
|
gptkbp:lifespan
|
8 to 9 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
gptkb:stock_market_index
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
linear
modulates neurotransmitter release
|
|
gptkbp:population
|
adults and children
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_information_on
|
dose adjustment for renal impairment
follow-up required
recommended for refractory epilepsy
|
|
gptkbp:regulatory_compliance
|
FDA approved
EMA approved
|
|
gptkbp:research_focus
|
new formulations
pediatric use
long-term safety
drug combinations
|
|
gptkbp:side_effect
|
gptkb:historical_event
anxiety
dizziness
fatigue
nausea
irritability
ataxia
insomnia
weight gain
somnolence
|
|
gptkbp:social_structure
|
pyrrolidine derivative
|
|
gptkbp:treatment
|
adjunctive therapy
|
|
gptkbp:type_of
|
357336-20-0
|
|
gptkbp:type_of_care
|
important for efficacy
|